Radiopharm Theranostics (RADX) Stock: Buy, Sell, or Hold?
RADX - Radiopharm Theranostics Limited American Depositary Shares
$1.52
-0.13 (-7.88%)
▼
5d:
-5.59%
30d:
-32.74%
90d:
-64.9%
HOLD
LOW Confidence
Analysis Updated: Sep 28, 2026 12:00 AM ET
Earnings: Feb 26, 2026
0d
Get Alerted When RADX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: RADX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: RADX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: RADX is currently trading at $1.52, which is considered oversold relative to its 30-day fair value range of $1.67 to $2.31.
Technical Outlook: Technically, RADX is in a strong downtrend. Immediate support is located at $1.44, while resistance sits at $2.00. Short-term momentum is weak, with the stock down 7.9% recently.
Market Sentiment: RADX scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $17.13 (+1027.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, RADX is in a strong downtrend. Immediate support is located at $1.44, while resistance sits at $2.00. Short-term momentum is weak, with the stock down 7.9% recently.
Market Sentiment: RADX scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $17.13 (+1027.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.67 -
$2.31
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (68/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.9%)
- BULLISH: Trading 1027.2% below Wall St target ($17.13)
- CAUTION: Bottoming setup, but lagging the sector by 45% over 20 days — wait for relative strength
- CAUTION: 5-day price weakness (-5.6%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$1.67 -
$2.31
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.44
Resistance Level
$2.00
Current Trend
Strong Downtrend
Technical data as of
Sep 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.47
Wall Street Target
$17.13
(+1027.2%)
Revenue Growth (YoY)
-27.6%
Share & Embed Analysis
Last updated: September 29, 2026 7:44 AM ET
Data refreshes hourly during market hours. Next update: 8:44 AM
Data refreshes hourly during market hours. Next update: 8:44 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RADX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$92 | 44 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 72 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 60 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 60 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 40 SELL |
